Strategic allocation of cash on hand
First written in FY2018. 6 of 10 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.
26 other companies' latest entry also says "Raised".
- FY2026RaisedAnnual report
「We plan to make total growth investments of ¥280 billion over the BSP2030 period. We plan to focus on projects with high strategic significance under BSP2030 and relatively early potential for harvesting benefits, including M&A and capital investments in the functional materials manufacturing business.」
For growth investment, the planned amount was increased from ¥200 billion under BSP2025 to a total of ¥280 billion under BSP2030. - FY2024-Q3RestatedAnnual report
「In addition, through the corporate venture capital fund “JGC MIRAI Innovation Fund,” the company invested in Biome Inc., which builds and operates a platform for visualising biodiversity information; Kyoto Fusioneering Ltd., which has advanced technology in the fusion field; GITAI Japan Inc., which conducts R&D and manufactures work robots for space; and nat Inc., which digitises the recording of spatial information.」
Growth investments through the CVC fund in biological information, fusion energy, space robotics and spatial information are continuing. - FY2024-Q2AdvancedAnnual report
「In addition, through the corporate venture capital fund “JGC MIRAI Innovation Fund,” the company invested in Biome Inc., which builds and operates a platform for visualising biodiversity information; Kyoto Fusioneering Ltd., which has advanced technology in the fusion field; GITAI Japan Inc., which conducts R&D and manufactures work robots for space; and nat Inc., which digitises the recording of spatial information.」
Through the CVC fund, in addition to biological information, fusion energy and space robotics, the company invested in nat株式会社, which digitizes spatial information, broadening its investment targets. - FY2024-Q1AdvancedAnnual report
「In addition, through the corporate venture capital fund “JGC MIRAI Innovation Fund,” the company invested in Biome Inc., which builds and operates a platform for visualising biodiversity information; Kyoto Fusioneering Ltd., which has advanced technology in the fusion field; and GITAI Japan Inc., which conducts R&D and manufactures work robots for space.」
Through the CVC fund, investments were made in 3 companies focused on biological information, fusion energy and space robotics, expanding the areas targeted for growth investments. - FY2023-Q2AdvancedAnnual report
「In addition, through the corporate venture capital fund “JGC MIRAI Innovation Fund,” established in the previous consolidated fiscal year, the company invested in a start-up developing next-generation perovskite solar cells, as well as various start-ups in healthcare, AI-equipped wearable devices and plant-based plastic alternatives.」
Through the CVC fund, investments were made in startups focused on perovskite solar cells, healthcare, AI-enabled wearables and plant-based plastic alternatives, expanding the areas targeted for growth investments. - FY2023-Q1AdvancedAnnual report
「In addition, through the corporate venture capital fund “JGC MIRAI Innovation Fund,” established in the previous consolidated fiscal year, the company invested in a start-up developing perovskite solar cells, which are expected to be next-generation solar cells, and a start-up with therapeutic technology for post-stroke motor impairments.」
Following the establishment of the CVC fund, specific investments were made in startups with technologies for perovskite solar cells and the treatment of post-stroke motor impairments. - FY2022-Q3AdvancedAnnual report
「Through the “JGC MIRAI Innovation Fund,” the company invested in TwoCells Co., Ltd., which is engaged in regenerative medicine using mesenchymal stem cells (MSCs), and MedRhythms Inc., which is developing digital therapeutics based on its proprietary music therapy for walking impairment in stroke patients.」
Following the establishment of the startup investment allocation and CVC fund, specific investments were made in 2 companies, one in regenerative medicine and one in digital therapeutics. - FY2022-Q1AdvancedAnnual report
「To establish future growth engines, the JGC Group newly set an investment framework totalling ¥10 billion for domestic and overseas start-ups. Within this framework, it established the corporate venture capital fund “JGC MIRAI Innovation Fund,” with total assets under management of ¥5 billion, together with Global Brain Corporation, an independent venture capital firm.」
For growth investments, a total investment allocation of ¥10 billion for domestic and overseas startups was newly established, and a CVC fund with total assets under management of ¥5 billion was established. - FY2020Improving liquidity and directing funds toward growth investmentsAnnual report
「In fiscal 2019, the recovery of advances paid for multiple projects under execution in Algeria progressed smoothly, significantly improving the liquidity of cash on hand. We intend to allocate these funds to growth investments going forward.」
The recovery of advances paid improved liquidity of cash on hand, and the company indicated that the recovered funds would be allocated to growth investments. - FY2018First statedAnnual report
「We will allocate cash on hand with the following targets in mind.」
The company indicated a target allocation of cash on hand of 30% to EPC working capital, 30% to growth strategy investments, 20% to shareholder returns, 10% to business investments and 10% to capital expenditure.